All News

Findings from the phase 3 COSMIC-311 trial led to the approval of cabozantinib in patients with radioactive iodine–refractory locally advanced or metastatic differentiated thyroid cancer.

Erdafitinib plus cetrelimab displayed strong responses for patients with metastatic or locally advanced urothelial carcinoma.

Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.

Patients with VHL-mutant and wild type clear cell renal cell carcinoma may have comparable clinical characteristics, although other genetic alterations may be at play.

A lack of understanding, communication, and more was expressed among both patients and caregivers regarding a subtype of kidney cancer.

Results of a phase 1/2 trial revealed the recommended phase 2 and maximum-tolerated dose of mobocertinib in Japanese patients with non–small cell lung cancer.

For patients with advanced EGFR Exon 20 Insertion–positive non–small cell lung cancer, mobocertinib appears to yield clinically meaningful activity compared with real-world data.

Findings from the phase 1b/2 MORPHEUS study indicated that patients with gastric and gastroesophageal junction cancer experienced limited responses to second-line linagliptin plus atezlolizumab.

Investigators identified a link between high tumor mutational burden and high responses to dostarlimab among patients with endometrial cancer.

Patients with advanced renal cell carcinoma experienced improvements in both progression-free and overall survival after being treated with first-line immunotherapy vs sunitinib, although the benefit is yet to be determined in those with favorable-risk disease.

Further results from the KEYNOTE-426 trial continue to support the combination of pembrolizumab plus axitinib in patients with clear cell renal cell carcinoma.

Results from the phase 2 ODEZA trial comparing patient preference of antiandrogen agents indicates benefits of darolutamide over enzalutamide in terms of certain cognitive functions in men with metastatic castration-resistant prostate cancer.

An examination of population-based Surveillance, Epidemiology, and End Results registries in Georgia and Louisiana from 2019 to 2020 determined that the diagnosis and treatment of various cancers were delayed due to the COVID-19 pandemic.

The FDA granted approval to the first oral therapy for advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations, mobocertinib.

Promising responses seen with the combination of pembrolizumab and olaparib in a cohort of patients with metastatic castration-resistant prostate cancer has led to the initiation of a phase 3 trial.

Patients with HER2-positive, metastatic biliary tract cancer experienced promising responses and a tolerable safety profile following treatment with pertuzumab plus trastuzumab.

Francesco Passamonti, MD, discusses the future of treatment for patients with polycythemia vera such as adaptive therapies and the utilization of novel targets.

Based on response data from the phase 2 MAGNOLIA trial, the FDA has granted accelerated approval to the Bruton tyrosine kinase inhibitor zanubrutinib to treat patients with relapsed/refractory marginal zone lymphoma.

Patients undergoing implant-based or autologous reconstruction and received adjuvant or neoadjuvant chemotherapy did not have an association with likelihood of complications compared with those who did not undergo chemotherapy.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about clinical benefits of using mobocertinib in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Progression-free survival lengths were different among patients with non-small cell lung cancer receiving sotorasib when stratified by genomic profile.

The first patients with human papillomavirus 16–positive oropharyngeal cancer have been dosed with ISA101b, which was given a fast track designation by the FDA, as part of a phase 2 study.

Patients who were carriers of pathogenic variants of for BRCA1/2 had a better physical and mental quality of life after undergoing risk-reducing salpingectomy compared with risk-reducing salpingo-oophorectomy.

The latest episode of CancerNetwork®’s podcast examines an initiative to diversify patient populations in oncology clinical trials and increase accessibility to these opportunities.

Patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma appeared to benefit from treatment with pirtobrutinib.

With the combination of mobocertinib and T-DM1, potent preclinical efficacy was observed in lung cancer cells with HER2 exon 20 insertion mutations.

Patients with resectable pleural mesothelioma underwent safe and effective treatment with the triplet combination of neoadjuvant cisplatin, pemetrexed, and atezolizumab from the ongoing S1619 trial.

Patients with newly diagnosed multiple myeloma experienced rapid responses and notable rates of minimal residual disease negativity following minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Findings from a phase 2 trial indicate that the use of neoadjuvant osimertinib may hold promise in a population of patients with EGFR-mutated non–small cell lung cancer.

Adjuvant atezolizumab led to disease-free survival benefit in patients with early-stage non–small cell lung cancer, including most patient subgroups, in the phase 3 IMpower010 trial.